<SEC-DOCUMENT>0001564590-21-015484.txt : 20210325
<SEC-HEADER>0001564590-21-015484.hdr.sgml : 20210325
<ACCEPTANCE-DATETIME>20210325161034
ACCESSION NUMBER:		0001564590-21-015484
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20210325
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210325
DATE AS OF CHANGE:		20210325

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Athira Pharma, Inc.
		CENTRAL INDEX KEY:			0001620463
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				453368487
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39503
		FILM NUMBER:		21772461

	BUSINESS ADDRESS:	
		STREET 1:		18706 NORTH CREEK PARKWAY, SUITE 104
		CITY:			BOTHELL
		STATE:			WA
		ZIP:			98011
		BUSINESS PHONE:		(206) 221-8112

	MAIL ADDRESS:	
		STREET 1:		18706 NORTH CREEK PARKWAY, SUITE 104
		CITY:			BOTHELL
		STATE:			WA
		ZIP:			98011

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	M3 Biotechnology, Inc.
		DATE OF NAME CHANGE:	20140924
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>atha-8k_20210325.htm
<DESCRIPTION>8-K
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
atha-8k_20210325.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="border-bottom:Double 2.25pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="AGM_Results"></a><a name="AGM_Results"></a>UNITED STATES</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Washington, DC 20549</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;<font style="font-size:10pt;">_______________________________</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FORM 8-K</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">__________________________</p>
<p style="text-align:center;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;<font style="font-weight:bold;font-size:12pt;">CURRENT REPORT</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to Section&#160;13 or 15(d) of the Securities Exchange Act of 1934</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Date of Report (Date of earliest event reported): March 25, 2021</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">_______________________________</p>
<p style="text-align:center;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> <font style="font-weight:bold;font-size:24pt;">Athira Pharma, Inc.</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Exact name of registrant as specified in its charter)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;<font style="font-size:10pt;">&#160;________________________________</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr style="height:14pt;">
<td valign="top"  style="padding-left:3pt;padding-Right:3pt;width:33.34%;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Delaware</p></td>
<td valign="top"  style="padding-left:3pt;padding-Right:3pt;width:33.34%;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">001-39503</p></td>
<td valign="top"  style="padding-left:3pt;padding-Right:3pt;width:33.34%;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">45-3368487</p></td>
</tr>
<tr style="height:20pt;">
<td valign="bottom"  style="padding-left:3pt;padding-Right:3pt;width:33.34%;">
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(State or other jurisdiction</p>
<p style="text-align:center;margin-bottom:2pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">of incorporation)</p></td>
<td valign="bottom"  style="padding-left:3pt;padding-Right:3pt;width:33.34%;">
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Commission</p>
<p style="text-align:center;margin-bottom:2pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">File Number)</p></td>
<td valign="bottom"  style="padding-left:3pt;padding-Right:3pt;width:33.34%;">
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(IRS Employer</p>
<p style="text-align:center;margin-bottom:2pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Identification No.)</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">18706 North Creek Parkway, Suite 104<br />Bothell, WA 98011</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Address of principal executive offices, including zip code)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(206) 221-8112</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Registrant&#8217;s telephone number, including area code)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:8pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Former name or former address, if changed since last report)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;_________________________________</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:0.59%;width:512pt;;">
<tr>
<td style="width:30pt;"></td>
<td style="width:482pt;"></td>
</tr>
<tr style="height:15pt;">
<td valign="top"  style="padding-left:3pt;padding-Right:2pt;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></p></td>
<td valign="top"  style="padding-left:3pt;padding-Right:2pt;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td>
</tr>
<tr style="height:15pt;">
<td valign="top"  style="padding-left:3pt;padding-Right:2pt;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></p></td>
<td valign="top"  style="padding-left:3pt;padding-Right:2pt;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p></td>
</tr>
<tr style="height:15pt;">
<td valign="top"  style="padding-left:3pt;padding-Right:2pt;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></p></td>
<td valign="top"  style="padding-left:3pt;padding-Right:2pt;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p></td>
</tr>
<tr style="height:15pt;">
<td valign="top"  style="padding-left:3pt;padding-Right:2pt;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></p></td>
<td valign="top"  style="padding-left:3pt;padding-Right:2pt;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p></td>
</tr>
</table></div>
<p style="margin-bottom:10pt;margin-top:10pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section 12(b) of the Act:</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr style="height:15pt;">
<td valign="bottom"  style="padding-left:3pt;padding-Right:3pt;width:33.2%;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Title of each class</p></td>
<td valign="bottom"  style="padding-left:3pt;padding-Right:3pt;width:33.4%;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Trading Symbol(s)</p></td>
<td valign="bottom"  style="padding-left:3pt;padding-Right:3pt;width:33.4%;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name of each exchange on which registered</p></td>
</tr>
<tr style="height:24pt;">
<td valign="top"  style="padding-left:3pt;padding-Right:3pt;width:33.2%;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common Stock, $0.0001 par value per share</p></td>
<td valign="top"  style="padding-left:3pt;padding-Right:3pt;width:33.4%;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ATHA</p></td>
<td valign="top"  style="padding-left:3pt;padding-Right:3pt;width:33.4%;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Nasdaq Stock Market LLC <br />(The Nasdaq Global Select Market)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:0.59%;width:479pt;;">
<tr>
<td style="width:130pt;"></td>
<td style="width:349pt;"></td>
</tr>
<tr style="height:15pt;">
<td valign="top"  style="padding-left:3pt;padding-Right:2pt;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Emerging Growth Company</p></td>
<td valign="top"  style="padding-left:3pt;padding-Right:2pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Segoe UI Symbol;letter-spacing:-0.1pt;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#9746;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9.5pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act).&#160;&#160;&#160;<font style="font-family:'Times New Roman';"><font style="font-size:9pt;font-family:'Times New Roman'">&#9744;</font></font></p>
<p style="border-bottom:Double 2.25pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9.5pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><br /></p><a name="_AEIOULastRenderedPageBreakAEIOU1"></a>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><a name="_AEIOULastRenderedPageBreakAEIOU2"></a>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;2.02 Results of Operations and Financial Condition.</p>
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.03%;">On March 25, 2021, Athira Pharma, Inc. (the &#8220;Company&#8221;) issued a press release reporting its financial results for the quarter and year ended December 31, 2020. A copy of the press release is furnished herewith as Exhibit 99.1.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I<font style="font-weight:bold;">tem 7.01 Regulation FD Disclosure.</font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:7.03%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company announces material information to the public through a variety of means, including filings with the Securities and Exchange Commission, press releases, public conference calls, the Company&#8217;s website (www.athira.com), its investor relations website (investors.athira.com), and its news site (investors.athira.com/news-and-events/press-releases). The Company uses these channels, as well as social media, including its Twitter account (@athirapharma), LinkedIn account (www.linkedin.com/company/athirapharma), and Facebook page (www.facebook.com/athirapharmainc), to communicate with investors and the public about the Company, its product candidates, and other matters. Therefore, the Company encourages investors, the media, and others interested in the Company to review the information it makes public in these locations, as such information could be deemed to be material information.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9.01 Financial Statements and Exhibits.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(d) Exhibits.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:0.59%;width:512pt;;">
<tr>
<td style="width:50pt;"></td>
<td style="width:4pt;"></td>
<td style="width:458pt;"></td>
</tr>
<tr style="height:20pt;">
<td valign="bottom"  style="padding-left:3pt;padding-Right:2pt; border-bottom:solid 1pt #000000;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit&#160;No.</p></td>
<td valign="bottom"  style="padding-left:3pt;padding-Right:0pt; border-bottom:solid 1pt transparent;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:3pt;padding-Right:2pt; border-bottom:solid 1pt #000000;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
</tr>
<tr style="height:17pt;">
<td valign="bottom"  style="padding-left:3pt;padding-Right:2pt;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99.1</p></td>
<td valign="bottom"  style="padding-left:3pt;padding-Right:0pt;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:3pt;padding-Right:3pt; border-top:solid 1pt #000000;">
<p style="text-align:justify;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="atha-ex991_19.htm"><font style="text-decoration:underline;">Athira Pharma, Inc. press release dated March 25, 2021</font></a></p></td>
</tr>
</table></div>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:7.03%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information furnished in this Current Report under Items 2.02 and 7.01 and the exhibit attached hereto shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">SIGNATURES</p>
<p style="margin-bottom:7pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.03%;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:0.59%;width:512pt;;">
<tr>
<td style="width:30pt;"></td>
<td style="width:268pt;"></td>
<td style="width:21pt;"></td>
<td style="width:193pt;"></td>
</tr>
<tr style="height:13pt;">
<td valign="top"  style="padding-left:3pt;padding-Right:0pt;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:3pt;padding-Right:0pt;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:3pt;padding-Right:0pt;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:3pt;padding-Right:2pt;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Athira Pharma, Inc.</p></td>
</tr>
<tr style="height:15pt;">
<td valign="bottom"  style="padding-left:3pt;padding-Right:0pt;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:3pt;padding-Right:0pt;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:3pt;padding-Right:0pt;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:3pt;padding-Right:0pt;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:14pt;">
<td valign="top"  style="padding-left:0pt;padding-Right:3pt; border-bottom:solid 1pt transparent;">
<p style="text-align:right;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date:</p></td>
<td valign="bottom"  style="padding-left:3pt;padding-Right:3pt; border-bottom:solid 1pt transparent;">
<p style="text-align:justify;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 25, 2021</p></td>
<td valign="top"  style="padding-left:3pt;padding-Right:2pt; border-bottom:solid 1pt transparent;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  style="padding-left:3pt;padding-Right:2pt; border-bottom:solid 1pt #000000;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Leen Kawas</p></td>
</tr>
<tr style="height:14pt;">
<td valign="top"  style="padding-left:3pt;padding-Right:0pt;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:3pt;padding-Right:0pt;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:3pt;padding-Right:0pt;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:3pt;padding-Right:2pt;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leen Kawas</p></td>
</tr>
<tr style="height:14pt;">
<td valign="top"  style="padding-left:3pt;padding-Right:0pt;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:3pt;padding-Right:0pt;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:3pt;padding-Right:0pt;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:3pt;padding-Right:2pt;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President and Chief Executive Officer</p></td>
</tr>
</table></div>
<p style="line-height:2pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>atha-ex991_19.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
atha-ex991_19.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 99.1</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gxgbt0cwlykm000001.jpg" title="" alt="" style="width:202px;height:100px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:14pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:14pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Athira Pharma Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Highlights</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;">-</font></p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-style:italic;font-family:Calibri;color:#000000;">LIFT-AD and ACT-AD studies evaluating ATH-1017, a once-daily investigational drug for the treatment of mild-to-moderate Alzheimer&#8217;s disease, actively enrolling patients &#8211;</font></p></td></tr></table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;">-</font></p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-style:italic;font-family:Calibri;color:#000000;">IND submissions planned for Parkinson&#8217;s disease dementia program in 1H 2021 and neuropsychiatric program by end of 2021 &#8211;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;">-</font></p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-style:italic;font-family:Calibri;color:#000000;">Raised $103.5M in follow-on public offering during first quarter of 2021 -</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk25133105"></a>BOTHELL, WA. March 25, 2021<font style="font-weight:normal;"> &#8212;<a name="_Hlk25133105"></a> </font><font style="text-decoration:underline;font-weight:normal;">Athira Pharma, Inc.</font><font style="font-weight:normal;"> (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today reported financial results for the fourth quarter and full year ended December 31, 2020 and provided recent business highlights. </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;2020 was a momentous year for the Athira team, particularly as we initiated two trials evaluating ATH-1017. The goal of the ACT-AD and LIFT-AD studies is to demonstrate the clinical utility of this promising agent to treat Alzheimer&#8217;s disease and preserve cognitive health. Alzheimer&#8217;s disease is an area of immense medical need and we are actively enrolling patients with the aim of reporting data in 2022,&#8221; said Leen Kawas, Ph.D., President and Chief Executive Officer at Athira. &#8220;Our novel treatment approach is agnostic to the underlying disease pathology and focuses on network recovery and information transmission in the brain, which has the potential to improve clinical outcomes for patients. Our compounds have potential in a broad range of clinical applications, and we look forward to submitting INDs for our Parkinson&#8217;s disease dementia program as well as our neuropsychiatric program this year. With our recently completed follow-on public offering, our balance sheet places us in a strong position to execute on our goals.&#8221;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Recent Business Highlights and Anticipated Milestones</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Calibri;font-size:11pt;font-weight:normal;text-transform:none;font-variant: normal;">Pipeline </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">ATH-1017: <font style="font-weight:normal;">A small molecule therapeutic specifically designed to enhance the activity of Hepatocyte Growth Factor (HGF) and its receptor, MET, which are expressed in normal central nervous system function, in order to impact neurodegeneration and regenerate brain tissue.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:11pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;font-family:Calibri;color:#000000;">ACT-AD trial actively enrolling patients. </font><font style="font-family:Calibri;color:#000000;">In November 2020, Athira initiated patient dosing in a randomized, placebo-controlled Phase 2 clinical trial evaluating ATH-1017, a once-daily investigational drug for the treatment of mild-to-moderate Alzheimer&#8217;s disease. The trial will enroll up to approximately 75 patients in the United States and Australia. Participants will be randomized across two dose groups and one placebo group on a 1:1:1 basis to receive a daily subcutaneous injection of ATH-1017 or placebo over a treatment course of 26 weeks and will be evaluated for improvement in cognition, global, and functional assessments comparing treatment arms to placebo. ACT-AD will also use electroencephalogram (EEG), to measure quantitative electroencephalogram (qEEG), and Event-Related-Potential (ERP P300), a functional measure of working memory processing speed and executive function. Results from the ACT-AD trial may provide Athira with information to help support strategic decisions around any additional trials of ATH-1017 Athira may conduct. Athira expects to report top-line data by early 2022.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:11pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;font-family:Calibri;color:#000000;">LIFT-AD actively enrolling patients. </font><font style="font-family:Calibri;color:#000000;">In September 2020, Athira initiated patient dosing in a randomized, double-blind, placebo-controlled Phase 2/3 clinical trial evaluating the safety, efficacy and tolerability of ATH-1017 in individuals with mild-to-moderate Alzheimer&#8217;s disease. Clinical efficacy will be measured by improvement in cognition and global/functional assessments comparing treatment arms to placebo. Up to approximately 300 patients will be randomized across two dose groups and one placebo group on a 1:1:1 basis to receive a daily subcutaneous injection of ATH-1017 or placebo over a treatment course of 26 weeks. Athira expects to report top-line data by the end of 2022.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:11pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;font-family:Calibri;color:#000000;">Phase 2 Parkinson&#8217;s disease dementia trial to begin by the end of 2021. </font><font style="font-family:Calibri;color:#000000;">Athira expects to submit an Investigational New Drug (IND) Application to the U.S. Food and Drug Administration (FDA) by the first half of 2021 and start a Phase 2 trial by the end of 2021. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">ATH-1019/1020: <font style="font-weight:normal;">Novel, small molecule compounds designed to be an orally available once-daily treatment, to activate the HGF/MET system, and to distribute to the CNS as potential candidates for neuropsychiatric indications, including depression, anxiety, and potentially schizophrenia.</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:11pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;font-family:Calibri;color:#000000;">IND filing expected by end of 2021. </font><font style="font-family:Calibri;color:#000000;">Athira is advancing ATH-1019 and ATH</font><font style="font-family:Cambria Math;color:#000000;">&#8209;</font><font style="font-family:Calibri;color:#000000;">1020 to further development for neuropsychiatric indications and is targeting an IND submission to the FDA by the end of 2021. Late-stage non-clinical development work and potentially early clinical studies will support decisions on selection of the lead product candidate and indication moving forward.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;text-indent:0%;font-style:italic;font-family:Calibri;font-size:11pt;font-weight:normal;text-transform:none;font-variant: normal;">Corporate</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:11pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;font-family:Calibri;color:#000000;">Raised $103.5 million from follow-on public offering. </font><font style="font-family:Calibri;color:#000000;">In February 2021, Athira announced that it completed a follow-on public offering raising total gross proceeds of $103.5 million, including the underwriters fully exercising their option to purchase an additional 600,000 shares of common stock.</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:11pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:11pt;"><font style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></font><font style="color:#000000;"></font><font style="font-weight:bold;font-family:Calibri;color:#000000;">Appoint</font><font style="font-weight:bold;font-family:Calibri;color:#000000;">ment</font><font style="font-weight:bold;font-family:Calibri;color:#000000;"> </font><font style="font-weight:bold;font-family:Calibri;color:#000000;">of two new</font><font style="font-weight:bold;font-family:Calibri;color:#000000;"> Board </font><font style="font-weight:bold;font-family:Calibri;color:#000000;">members</font><font style="font-weight:bold;font-family:Calibri;color:#000000;">. </font><font style="font-family:Calibri;color:#000000;">In December 2020, </font><font style="font-family:Calibri;color:#000000;">Athira</font><font style="font-family:Calibri;color:#000000;"> announced the </font><font style="font-family:Calibri;color:#000000;">appointment of Kelly Romano to its Board of Directors. Ms. Romano is the Founder and Chief Executive Officer of </font><font style="font-family:Calibri;color:#000000;">BlueRipple</font><font style="font-family:Calibri;color:#000000;"> Capital, LLC, a consultancy firm for global technology companies</font><font style="font-family:Calibri;color:#000000;"> and brings over </font><font style="font-family:Calibri;color:#000000;">30 years of executive operating experience in technology</font><font style="font-family:Calibri;color:#000000;">.</font><font style="font-family:Calibri;color:#000000;"> In March 2021, </font><font style="font-family:Calibri;color:#000000;">Athira</font><font style="font-family:Calibri;color:#000000;"> announced the appointment of </font><font style="font-family:Calibri;color:#000000;">Barbara </font><font style="font-family:Calibri;color:#000000;">Kosacz</font><font style="font-family:Calibri;color:#000000;"> to its Board of Directors. Ms. </font><font style="font-family:Calibri;color:#000000;">Kosacz</font><font style="font-family:Calibri;color:#000000;"> is Chief Operating Officer and General Counsel at Kronos Bio, Inc., a clinical-stage </font><font style="font-family:Calibri;color:#000000;">oncology-focused </font><font style="font-family:Calibri;color:#000000;">biopharmaceutical compan</font><font style="font-family:Calibri;color:#000000;">y. Ms. </font><font style="font-family:Calibri;color:#000000;">Kosacz</font><font style="font-family:Calibri;color:#000000;"> is a nationally recognized </font><font style="font-family:Calibri;color:#000000;">life sciences attorney with over 25 years of experience.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:11pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;font-family:Calibri;color:#000000;">$15 million grant awarded from NIH to support ACT-AD trial. </font><font style="font-family:Calibri;color:#000000;">In October 2020, Athira announced that it was awarded a research grant expected to total $15.2 million over three years from the National Institute on Aging (NIA) of the National Institutes of Health (NIH) to support its ACT-AD trial.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:11pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;font-family:Calibri;color:#000000;">Completed upsized initial public offering (IPO). </font><font style="font-family:Calibri;color:#000000;">In September 2020, Athira completed its IPO, generating gross proceeds of $204.0 million. In October 2020, Athira sold and issued an additional 1,397,712 shares of common stock upon the partial exercise of the underwriters to purchase additional shares, for additional gross proceeds of $23.8 million.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Fourth Quarter and Full Year 2020 Financial Results</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;color:#000000;">Cash Position. </font><font style="color:#000000;">Cash, cash equivalents and marketable securities were $268.2 million as of December 31, 2020, as compared to $2.1 million as of December 31, 2019.&nbsp;&nbsp;Based upon its current operating plan, Athira estimates that its existing cash, cash equivalents and investments as of December 31, 2020 will be sufficient to fund its operating expenses and capital expenditure requirements at least through 2022.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;color:#000000;">Research and Development (R&amp;D) Expenses. </font><font style="color:#000000;">R&amp;D expenses were $5.2 million for the quarter and $13.3 million for the full year ended December 31, 2020, compared to $0.7 million and $3.8 million for the same quarter and year in 2019. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;color:#000000;">General and Administrative (G&amp;A) Expenses: </font><font style="color:#000000;">G&amp;A expenses were $3.9 million for the quarter and $6.7 million for the full year ended December 31, 2020, compared to $0.5 million and $1.7 million for the same quarter and year in 2019.</font><font style="font-weight:bold;color:#000000;"> </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;color:#000000;">Net Loss: </font><font style="color:#000000;">Net loss was $7.7 million, or a net loss of $0.24 per share basic and diluted, for the quarter and $19.9 million, or $1.67 per share, for the year ended December 31, 2020 compared to $1.0 million, or a net loss of $0.27 per share basic and diluted, for the same quarter in 2019 and $5.2 million, or $1.45 per share, for the year ended December 31, 2019.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">About Athira Pharma, Inc.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Athira, headquartered in the Seattle area, is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration. We aim to provide rapid cognitive improvement and alter the course of neurological diseases with our novel mechanism of action. Athira is currently advancing its lead therapeutic candidate, ATH-1017, a novel small molecule for </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Alzheimer&#8217;s</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and Parkinson&#8217;s dementia</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> For more information, visit </font><font style="color:#auto;text-decoration:underline;">www.athira.com</font><font style="text-decoration:underline;">.</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> You can also follow Athira on </font><font style="color:#auto;text-decoration:underline;">Facebook</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </font><font style="color:#auto;text-decoration:underline;">LinkedIn</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;and&#160;@athirapharma on </font><font style="color:#auto;text-decoration:underline;">Twitter</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and </font><font style="color:#auto;text-decoration:underline;">Instagram</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Forward-Looking Statements</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are not based on historical fact and include statements regarding ATH-1017 as a potential treatment for Alzheimer&#8217;s disease and other dementias; Athira&#8217;s platform technology and potential therapies; future development plans; clinical and regulatory objectives and the timing thereof; anticipated design of planned clinical trials; expectations regarding the potential efficacy and commercial potential of Athira&#8217;s product candidates, including ATH-1017; the anticipated presentation of data; the results of Athira&#8217;s research and development efforts; Athira&#8217;s ability to advance its product candidates into later stages of development; and Athira&#8217;s expectation of having sufficient cash, cash equivalents and investments to fund its operations at least through 2022. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words and phrases such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "pursue," &#8220;continue,&#8221; and other similar expressions, among others. Any forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the preliminary data for Athira&#8217;s ATH-1017 product candidate from the Phase 1a/b trials will not continue or persist; cessation or delay of any of the ongoing clinical trials and/or Athira&#8217;s development of ATH-1017 may occur; future potential regulatory milestones of ATH-1017, including those related to current and planned clinical studies may be insufficient to support regulatory submissions or approval; the impact of the COVID-19 pandemic on Athira&#8217;s business, research and clinical development plans and timelines and results of operations, including impact on Athira&#8217;s clinical trial sites and contractors who act for or on Athira&#8217;s behalf, may be more severe and more prolonged than currently anticipated, clinical trials may not demonstrate safety and efficacy of any of Athira&#8217;s product candidates; Athira&#8217;s assumptions regarding its planned expenditures and sufficiency of its cash, cash equivalents and investments to fund operations may be incorrect; Athira&#8217;s research and development efforts and its ability to advance product candidates into later stages of development may fail; any one or more of Athira&#8217;s product candidates may not be successfully developed, approved or commercialized; adverse conditions in the general domestic and global economic markets; regulatory uncertainty as a result of the new U.S. administration; regulatory agencies may be delayed in reviewing, commenting on or approving any of Athira&#8217;s clinical development plans as a result of the COVID-19 pandemic, which could further delay development timelines; the impact of competition; the impact of expanded product development and clinical activities on operating expenses; impact of new or changing laws and regulations; as well as the other risks detailed in Athira&#8217;s filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof and Athira undertakes no obligation to update forward-looking statements. Athira may not actually achieve the plans, intentions, or expectations disclosed in its forward-looking statements, and you should not place undue reliance on the forward-looking statements.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"># # #</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Investor &amp; Media Contact<font style="font-weight:normal;">:</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Julie Rathbun</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Athira Pharma</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Julie.rathbun@athira.com</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">206-769-9219</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Athira Pharma, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="CONDENSED_CONSOLIDATED_BALANCE_SHEETS"></a><a name="CONDENSED_CONSOLIDATED_BALANCE_SHEETS"></a>Condensed Consolidated Balance Sheets</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Amounts in thousands)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Helvetica;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Helvetica;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Helvetica;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Helvetica;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Helvetica;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.02%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Helvetica;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Helvetica;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.96%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Helvetica;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.74%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Helvetica;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Helvetica;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Helvetica;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.32%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Helvetica;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.02%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Helvetica;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Helvetica;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Helvetica;font-style:normal;text-transform:none;font-variant: normal;">Assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.02%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;Cash and cash equivalents</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60,625</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,056</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;Short-term investments</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">124,057</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;Other short-term assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,655</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;Long-term investments</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83,509</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.96%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;Other long-term assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,717</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.96%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.74%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">279,563</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.32%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,189</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Helvetica;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Helvetica;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Helvetica;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Helvetica;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Helvetica;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Helvetica;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Helvetica;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.02%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Helvetica;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Helvetica;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Helvetica;font-style:normal;text-transform:none;font-variant: normal;">Liabilities, Convertible preferred stock and stockholders' equity (deficit)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;Current liabilities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,405</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,273</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;Long-term liabilities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">876</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,588</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,281</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,861</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Convertible preferred stock</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,051</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.96%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stockholders' equity (deficit)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">274,282</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19,723</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.96%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities and stockholders' equity (deficit)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.74%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">279,563</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.32%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,189</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Athira Pharma, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="CONDENSED_CONSOLIDATED_STATEMENTS_COMPRE"></a><font style="Background-color:#FFFFFF;"><a name="CONDENSED_CONSOLIDATED_STATEMENTS_COMPRE"></a>Condensed Consolidated Statements of Comprehensive Loss</font> </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Amounts in thousands)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:61.06%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Helvetica;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Helvetica;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.28%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Helvetica;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Helvetica;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:61.06%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Helvetica;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Helvetica;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Helvetica;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Helvetica;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Helvetica;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Helvetica;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Helvetica;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,286</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,793</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:61.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,709</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,656</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:61.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,995</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,449</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19,995</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,449</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Grant Income</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,321</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">754</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:61.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income (expense), net</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,281</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(466</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:61.06%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19,955</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,161</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:61.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrealized (loss)/gain on available-for-sale securities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.52%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:61.06%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive loss attributable to common shareholders</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19,922</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,161</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:61.06%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share attributable to common stockholders,</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; basic and diluted</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.52%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.67</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.45</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:61.06%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average shares used in computing net loss per</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; share attributable to common stockholders, basic</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; and diluted</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.52%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,966,912</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,566,849</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>gxgbt0cwlykm000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gxgbt0cwlykm000001.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %8 K4# 2(  A$! Q$!_\0
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M:_#O1%NY(C<W4S>7;VX.-[>I/8"O-/"7[2DVH:W;VFL:=#!:SN(Q/ QS&2<
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MVF8<[^S%O[]/U/K.+*WL\OY%]J27W:_H=R*6BBOV4_& HHHH **** "BBB@
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MR"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBD)Q0 $XKY:^/?Q#_ .$IU\:39RYT
MRP8AF!XEE[GZ#H/QKUCXX_$5?!V@&QM) -5OE*I@\QIW;^@KY4+;B2Q))Y)/
M>OS3BO-;+ZA2?G+]%^K^1^F<*95=_7ZR\H_J_P!%\RUI.E7&MZG;6%HGF7%P
MX1%'O7<?&308/"FHZ+HL &+2Q&]A_$['+$_C7H7[.OP[^R6S>)K^/$TP*6B,
M/NIW?\>GTKAOVA9O-^)-P,@[+>)>/H:^>GESPF3O%5%[U1JWE'?\;7^X^BAF
M*Q><+"TW[M--OSEHOPO;UN<_\*K3[9\2/#T?7;=K)C_=Y_I7V:*^2/@-;^?\
M4M)R,A$F<_A&V/UKZW%?8<'PM@JDN\OR2/C>,9WQM.':/YMBT445]X?!A111
M0 4444 %%%5M0O8=,LKB[N'$<%O&TLCGHJ@9)_(4 ,GUBPM93'->V\4@ZH\H
M!'X9J/\ X2#3/^@C:_\ ?Y?\:_*'XC>/[_QUXZUO7FNIE2]N7DB59& 6/.$
M_ "N<&I7G_/W<?\ ?UO\:]M9:VDW+\#SWBM=$?L3:ZA:WV[[/<13[>OEN&Q^
M56*_/+]BCXCS>'?BL='O+J1[3683"!(Y($J\KU/U%?H8M>;B*#H3Y&[G72J>
MTC<6BBBN8U"BBB@ HHHH **** "BBB@ HHHH *KW5_;6(4W-Q% &Z&1PN?SJ
MQ7R)_P %!;F6WT/PJ8I7B)N),E&(S\H]*VHT_:U%"]KF=2?)%R/JO_A(-,_Z
M"-K_ -_E_P :/^$@TS_H(VO_ '^7_&OQ^_M*\_Y^[C_OZW^-']I7G_/W<?\
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M)0X]B!SZ$U^E%>#BJ"H5.5;'HT:GM(W84445QFX4444 %%%% !1110 4444
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MMH9+$0D[(^TJ***\XZ@HHHH *^0?^"A?_(#\*?\ 7Q)_Z#7U]7R#_P %"_\
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MN0V"BBB@ HHHH **** $HI:* ,G7_#&E>*;)K75+**\A/3S%Y7W!ZC\*\/\
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M&O\ &3XW^6MQH7AZ?]X<I<7L9^Z.ZH?7WKP ^I.3W)-)7M'P<^"3:V\.LZ_
M5T\8:&T?@S>A;_9]N]?EDYXWB/&66_X17]?-GZI"&"X<P=WM^,G_ %\D-^"O
MP<.NRP:]K,1&GH=UO;N/]<1T)']W^=?2:*%4   #@ =J2*-88UC1 B*,*JC
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M'Q$5&>A?T+7+WPSK5EJVG3-;WMG*LT4BG!# Y_+M7ZO_  M\;P_$?P!H?B.
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ME[:9XS^>17YCP?5Y,;.G_-'\FC].XPI<V"A4_EE^:/4**3K2U^OGY %%%(:
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MUATKZ3+OX+]?\CR\5\:]!:^T_P#@G?\ \@WQI_UWM_\ T%J^+*^T_P#@G?\
M\@WQI_UWM_\ T%JUQW\"7]=3/#_Q4?8M<)\=?^2.^,/^P;-_Z":[NN$^.O\
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M7A?[8WC_ /X0GX.7MO#)Y=]J[BRB /.T\N?^^1^HK2G!U)J"ZDRERQ<CX_\
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M^E=77SM62G4E)=6>G!.,4F%%%%9%A1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110!R'Q)^'MG\0-">UF CO(@6MK@#E&]/H>XKY!UG1
MKK0-4N-/OHS#=0-M92/U'M7W8>E>7_&OX7)XSTHZC8(%UFT4E<#_ %Z=T/OZ
M5\1Q'DJQM/ZU07[R._\ >7^:Z?<?<<.9V\%46%KO]W+;^Z_\GU^_N>#^ ?&W
M]@1:AI%^6ET35(6AF3_GDQ! <?CUKCV38[+D-M.,CH:5T9'9'4JZG!4C!!I
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M>C%+10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M *#<$GDA1\A/U7'Y5&.@YPC6:L^I6'DHR<+GMM?FC^V?_P E_P#$/_7&W_\
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MY6U;&5)5&X2LC.%""BN9:GR-XQ_8,\-Z?X6U6YT75-4GU6"W>6WBG9"CN!D
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
8 !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
